TY - JOUR T1 - Is vitamin D deficiency associated with the COVID-19 epidemic in Europe? JF - medRxiv DO - 10.1101/2021.01.28.21250673 SP - 2021.01.28.21250673 AU - Dimitra Rafailia Bakaloudi AU - Michail Chourdakis Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/29/2021.01.28.21250673.abstract N2 - Objective COVID-19 has emerged as a global pandemic, affecting nearly 80 million people from 218 countries as of December 2020. At the same time, vitamin D deficiency seems to be prevalent among COVID-19 patients. Hence, the association between the prevalence of vitamin D deficiency and COVID-19 infection and mortality among European countries was examined.Design A case series and recent literature review studySettings Information on prevalence of vitamin D deficiency in each country was retrieved through literature searching on PubMed® database. As of December, 23rd 2020, COVID-19 infections and mortalities per million population were extracted from the Worldometer website, whereas the latitude of each country was taken from the CSGNetwork website. The association between both vitamin D deficiency and COVID-19 infection and mortality were explored using correlation coefficients and scatterplots.Participants European Countries-PopulationsResults The range of prevalence of vitamin D deficiency among European countries was 6.9-75.1%, with most countries facing more than 50% of vitamin D deficiency among their population. Significant positive correlations were observed between COVID-19 infections (r=0.82; p<0.001) and mortalities (r=0.53; p=0.05) per million population with the prevalence of vitamin D deficiency. Most of the high latitude countries showed lower rates of COVID-19 infections and mortalities compared to middle latitude countries.Conclusion Prevalence of vitamin D deficiency was significantly associated with both infection and mortality rate of COVID-19 among European countries. Thus, it is an important parameter to be considered when implementing preventive measures to mitigate the mortality rate of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no specific grant from any funding agency, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCOVID-19 infections and mortalities per million population were extracted from the Worldometer website, whereas the latitude of each country was taken from the CSGNetwork website https://www.worldometers.info/coronavirus/ 1MOne million25(OH)D25-hydroxyvitamin D3ACE2Angiotensin-Converting Enzyme 2Ang (1-7)Angiotensin (1-7)ARSAcute Respiratory SyndromeCOVID-19Coronavirus disease 2019ECTSEuropean Calcified Tissue SocietyICUIntensive Care UnitISOInternational Organization for StandardizationMasRMas ReceptorPCRPolymerase Chain ReactionRASRenin - Angiotensin SystemRICURespiratory Intermediate Care UnitSARS-CoV-2Severe Acute Respiratory Syndrome CoronavirusUVUltravioletUVBUltraviolet BVit DVitamin D ER -